Skip to main content
. Author manuscript; available in PMC: 2010 Jul 17.
Published in final edited form as: Cancer. 2010 Feb 1;116(3):640–646. doi: 10.1002/cncr.24767

Figure 1.

Figure 1

A representative sample of residual monoclonal protein (rM-protein) trends through the first 4 cycles of treatment is shown. rM-protein indicates the percentage of serum monoclonal protein remaining relative to the baseline level.